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Background. The objective of this trial was to determine the effectiveness of 1.0% C31G (SAVVY) in preventing male-to-female
vaginal transmission of HIV infection among women at high risk. Methodology/Principal Findings. This was a Phase 3,
double-blind, randomized, placebo-controlled trial. Participants made up to 12 monthly follow-up visits for HIV testing,
adverse event reporting, and study product supply. The study was conducted between September 2004 and December 2006 in
Lagos and Ibadan, Nigeria, where we enrolled 2153 HIV-negative women at high risk of HIV infection. Participants were
randomized 1:1 to SAVVY or placebo. The effectiveness endpoint was incidence of HIV infection as indicated by detection of
HIV antibodies in oral mucosal transudate (rapid test) or blood (ELISA), and confirmed by Western blot or PCR testing. We
observed 33 seroconversions (21 in the SAVVY group, 12 in the placebo group). The Kaplan-Meier estimates of the cumulative
probability of HIV infection at 12 months were 0.028 in the SAVVY group and 0.015 in the placebo group (2-sided p-value for
the log-rank test of treatment effect 0.121). The point estimate of the hazard ratio was 1.7 for SAVVY versus placebo (95%
confidence interval 0.9, 3.5). Because of lower-than-expected HIV incidence, we did not observe the required number of HIV
infections (66) for adequate power to detect an effect of SAVVY. Follow-up frequencies of adverse events, reproductive tract
adverse events, abnormal pelvic examination findings, chlamydial infections and vaginal infections were similar in the study
arms. No serious adverse event was attributable to SAVVY use. Conclusions/Significance. SAVVY did not reduce the
incidence of HIV infection. Although the hazard ratio was higher in the SAVVY than the placebo group, we cannot conclude
that there was a harmful treatment effect of SAVVY. Trial Registration. ClinicalTrials.gov NCT00130078
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INTRODUCTION
Heterosexual contact accounts for the majority of all human
immunodeficiency virus (HIV) infections worldwide, [2] and clear
need exists for new technologies to prevent the sexual transmission
of HIV. Despite years of effort, an effective HIV-1 vaccine remains
elusive. Correct and consistent male condom use has been shown
to prevent HIV-1 transmission, [3] but women are often unable to
obligate or negotiate the use of condoms by their male partners.
Additional strategies to prevent the spread of HIV, particularly for
women who are at high risk for HIV acquisition, are crucial.
Topical microbicides are products that are designed to inhibit the
sexual transmission of HIV and other sexually transmitted
infections (STIs). [4] Microbicides could potentially be applied
vaginally to prevent both male-to-female and female-to-male
transmission; by offering a female-controlled prophylactic option,
a microbicide would be an important addition to the prevention
toolkit. Unfortunately, no clinical studies to date have demon-
strated that these products can prevent HIV infection, [5] and
spermicides with the surfactant nonoxynol-9 (N-9) have caused
mucosal erosion and ulceration, which may increase the risk of
HIV acquisition. [6,7]
C31G (SAVVYH) has a potent effect on enveloped HIV in vitro
through a mechanism by which it disrupts the outer membrane.
[8] Because its mechanism of action is similar to N-9, [8,9] some
have raised concerns about the safety of C31G. Four Phase 1
studies conducted using three concentrations of C31G (0.5%,
1.0%, 1.7%) assessed signs and symptoms of irritation, epithelial
disruption, vaginal colonization, vaginal leakage, and systemic
absorption. Signs of irritation were reported, but no serious or
severe adverse events related to use of 1.0% C31G gel occurred,
and it was less toxic than N-9. [9–12] A fifth colposcopy study
reported more complaints of discomfort in the C31G users, but
similar colposcopic findings of epithelial disruption among users of
1.2% C31G and 2% N-9. [13] The 1.0% concentration was
selected by the developer, Biosyn, Inc., for larger-scale testing as
SAVVYH. We investigated the safety and effectiveness of 1.0%
SAVVY in preventing male-to-female transmission of HIV in a
population of young, sexually active Nigerian women at high risk.
METHODS
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
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We conducted this randomized, double-blind, placebo-controlled
trial between September 2004 and December 2006 in Lagos and
Ibadan, Nigeria. We enrolled HIV-antibody negative, non-
pregnant women between 18–35 years old who reported more
than two coital acts per average week and more than one sex
partner in the last three months. Study outreach staff recruited
participants from local market areas, bars, hostels, military
barracks and colleges, but not brothels. Each study site had two
central clinics and 10 peripheral outreach offices spread over
various sections of the city. Outreach workers referred interested
women to the central clinic.
Ethics
The study protocol and informed consent forms were approved
by: 1) the University of Ibadan/University College Hospital
Institutional Review Committee, Ibadan, Nigeria; 2) the Nigerian
Institute of Medical Research Institutional Review Board, Lagos,
Nigeria; and 3) the Protection of Human Subjects Committee,
Family Health International (FHI), NC, USA.
Study counselors read informed consents with each potential
participant in the woman’s preferred language (English, pidgin or
Yoruba). Independent participant advocates witnessed the consent
processes for all illiterate women and any other woman who
requested one. Prior to signature or fingerprint mark, each woman
was asked questions about the information in the consent form to
assess her comprehension of the study procedures and purpose.
Interventions
Consenting women underwent eligibility confirmation and then
pregnancy testing; rapid HIV testing with pre- and post-test
counseling; physical and pelvic exams; tests for chlamydia,
gonorrhea and syphilis; and microscopic examination of vaginal
specimens for trichomoniasis, candidiasis, and bacterial vaginosis.
Women who were pregnant or HIV rapid test-reactive were
screening failures and not enrolled. Women who were confirmed
HIV-positive were referred to PEPFAR treatment programs at
each institution for monitoring and care. We asked women
confirmed eligible at the screening visit to return within 42 days for
enrollment. At the enrollment visit, participants received a second
informed consent explaining the details of the study. If interested
and eligible for the study, participants who signed the enrollment
consent form underwent pregnancy testing, rapid HIV testing and
family planning counseling and referral to services if requested.
Participants were then randomized to receive SAVVY or placebo
gel, given a supply of 60 condoms and 60 study gels (to last one
month), and scheduled to return for 12 monthly follow-up visits.
Staff instructed participants on proper condom use and gel
application and told them to return for more condoms and gel if
needed. Study staff counseled participants to use condoms at every
coital act; that gel effectiveness was unknown; and that they may
be receiving a placebo gel that is known not to protect against
HIV.
During each monthly follow-up visit at an outreach office,
participants answered structured questionnaires including infor-
mation on recent sexual behavior, condom and gel use, and
medical problems or medication use since the previous visit.
Participants underwent pregnancy and HIV rapid testing and STI
risk-reduction counseling, and received a one-month supply of
condoms and study gels. At the 6-month follow-up visit,
participants returned to the main study clinic for pelvic exams
for STI and saline wet mount examinations of vaginal specimens.
We discontinued participants who became pregnant from product
use but they remained in the study for monitoring, HIV testing
and other data collection, and assessment of pregnancy outcomes.
If pregnancy ended during follow-up, a participant could re-start
product use. We discontinued participants who were confirmed
HIV positive from the study and referred them to the PEPFAR
program for care and antiretroviral therapy if needed. If a
participant reported any adverse events to the outreach worker
during follow-up, she was referred to the study clinic for evaluation
and STI testing as needed. If a participant missed a scheduled
follow-up visit, study staff made up to 3 attempts to contact that
participant and reschedule the visit. After 3 failed contact
attempts, no further efforts were made to find her, but her file
remained open until study closeout. If the participant did not
return to the study before the study was closed, she was considered
lost to follow-up at closeout.
Objectives
The primary objective of this trial was to determine the
effectiveness of 1.0% C31G (SAVVY) in preventing male-to-
female vaginal transmission of HIV infection among women at
high risk.
Outcomes
The primary measure of effectiveness was infection with HIV,
indicated by antibodies in oral mucosal transudate (OMT)
(OraQuickH ADVANCE Rapid HIV-1/2 Antibody Test, Orasure
Technologies), or by enzyme-linked immunosorbent assay (ELISA)
(Genetic Systems
TM HIV-1/HIV-2 Plus O ELISA from BioRad)
and confirmed by Western blot (Genetic Systems
TM HIV-1
Western Blot, BioRad) and/or polymerase chain reaction (PCR)
(Roche Amplicor 1.5) from a finger-prick or venous blood
specimen.
We tested OMT specimens at screening, enrollment, and then
monthly throughout follow-up using OraQuick. If the OraQuick
OMT specimen was reactive, we collected blood for ELISA and
Western blot and possible PCR testing. At the final follow-up visit
all participants received OraQuick OMT and ELISA tests; if
either was positive they also had Western blot and PCR tests. We
tested stored enrollment specimens using PCR for all participants
with HIV infection during follow-up to confirm that seroconver-
sion occurred after enrollment.
We evaluated safety by comparing the incidence of adverse
events (AEs), pelvic exam findings and STIs.
Sample Size
We estimated that a sample size of 2142 participants (1,071 in
each treatment group) would yield 80% power to detect a 50%
difference in the HIV infection rate (two-sided log-rank test with
a=0.05) between the two groups. With an assumed HIV infection
rate in the control group of 5/100 person-years and loss to follow-
up of 20%, we anticipated observing 66 HIV infections. [14–15]
The analysis plan included a blinded assessment of whether
additional participants would be needed to observe the required
66 events.
Randomization—Sequence Generation
We randomized enrolled participants to either SAVVY or placebo
using a 1:1 allocation ratio. An FHI statistician developed the
allocation sequence using a computer random number generator
and randomly varied permuted-blocks of size 12, 18, and 24,
stratified on site.
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Six label colors (three SAVVY and three placebo) were used to
differentiate the otherwise identically packaged gels. We used
sequentially numbered, sealed opaque envelopes to assign
participants to one of six color groups after they had qualified
for the study and signed the consent form. The randomization
envelopes were maintained in a secure office and were not
available to study staff until the moment of randomization. Each
randomization envelope was used only once.
Randomization—Implementation
An FHI statistician not otherwise involved with the study
developed the allocation sequence. Clinic managers assigned
participants to their study groups.
Blinding
Participants, field study staff, monitors, statisticians, and other FHI
staff involved in the trial were not aware of which gel colors were
associated with SAVVY or placebo. Both SAVVY and placebo
gels were clear, with similar viscosity and pH, dispensed in 3.5 mL
doses with identical applicators. The placebo gel was formulated
using hydroxyethylcellulose and sorbic acid to minimize any
possible effects on study endpoints. It was isotonic and had a pH of
4.4 but with minimal buffering capacity; when mixed with an
equal volume of semen, the placebo gel induced a trivial decrease
in semen pH (from 7.8 to 7.7). In a phase I clinical trial conducted
to assess the safety of the placebo gel, no serious or unexpected
AEs were reported following twice-daily intravaginal application
for 14 days in healthy sexually abstinent women. [16]
Statistical Methods
For the primary effectiveness analysis we compared the distribu-
tion of HIV-free survival times for the SAVVY and placebo gel
groups using a two-sided site-stratified log-rank test. We calculated
Kaplan-Meier estimates [17] of HIV infection probabilities by
treatment group, pooled across sites. We used a proportional
hazards regression model to estimate the hazard ratio and 95%
confidence intervals for incident HIV infection, comparing the
SAVVY group to the placebo group, with and without controlling
for site and other pre-planned baseline variables. We evaluated the
homogeneity of the treatment effect across sites, and the
proportional hazards assumption, and found no evidence of
violation of either at the 0.05 level. We estimated the HIV
infection onset date as the midpoint between the date of the first
confirmed positive test result and the previous, negative test date.
A right censoring time of 380 days was applied. Because the trial
was terminated for futility before reaching the number of HIV
infections targeted for pre-planned tests of effectiveness, p-values
for those analyses should be interpreted with caution. We
compared proportions of women with any pelvic exam findings
or STIs between treatment groups with a two-sided Mantel-
Haenszel Chi-Square Test stratified by site at the 0.05 significance
level.
All primary and most secondary analyses were either conducted
on the Effectiveness Population (a subset of the Intent-to-Treat
(ITT) Population for whom at least one post-enrollment HIV
evaluation is available), or the Safety Population which is the
subset of the ITT Population who returned after enrollment. The
Evaluable Population includes the same participants as the
Effectiveness Population but excludes all data collected from a
participant after her first documented interruption of product use.
We pre-specified that the independent Data Monitoring
Committee (DMC), with access to treatment assignments, would
review AEs and primary safety and HIV seroconversion data
twice, after approximately 16 and 33 events, respectively.
However, testing for early evidence of effectiveness was scheduled
to occur only at the second of these two planned looks and again
when the target number of events (66) was obtained, controlling
for the one planned interim effectiveness analysis. [14–15]
RESULTS
Recruitment and Participant Flow
The participant screening and enrollment phase began in
September 2004 and lasted 19 months. We enrolled 2,153 of
the 3,334 screened potential participants (Figure 1). The primary
reasons potential participants were not enrolled were because they
failed to return for enrollment or were HIV-infected or pregnant
at baseline. Follow-up continued until December 2006. Overall
loss to follow-up after enrollment was approximately 23%
(n=502), and was the same in each treatment group. Fifty-seven
participants never returned for a visit after enrollment, and were
excluded from the primary analyses. Due to premature termina-
tion of the study (see below), 286 participants completed their final
visits before their 12-month visit (Figure 1). Sixty-five additional
participants discontinued early, including three participants (one
in the SAVVY group and two in the placebo group) who died
during follow-up. The three deaths were unrelated to product use.
One participant in each treatment group discontinued for a
medical reason related to the product.
Numbers Analyzed
The ITT population comprised 2153 participants who were
consented, enrolled and randomized to treatment (1076 in the
SAVVY group and 1077 in the placebo group). Effectiveness
analyses were conducted on the Effectiveness Population, a subset
of the ITT Population with 2082 participants who had HIV
testing after enrollment (1041 in both SAVVY and placebo
groups; other women never returned for a follow-up visit or had
missing data). Safety endpoints were assessed in the Safety
Population, the subset of the ITT Population with 2088
participants who returned after enrollment and provided safety
data (1043 SAVVY and 1045 placebo). The Evaluable Population
included the same participants as the Effectiveness Population
(N=2082) but excluded person-time observed on a participant
after her first documented interruption of product use.
Baseline Data
Most ITT participants in both groups were young (mean age 23.6)
and unmarried (Table 1). The most commonly used contraceptive
method at baseline was the male condom (SAVVY 72.1%;
placebo 68.9%), with oral contraceptives next most frequent (8.9%
SAVVY; 8.3% placebo). Some participants also reported dual
method use. Most participants had received more than 9 years of
education, and were students, or worked in trade or commercial
jobs. Other demographic characteristics and medical history were
also similar in the two groups (Table 1). About 3.3% of ITT
participants were excluded from the Effectiveness Population, and
their sociodemographic features (not shown) were virtually the
same as the ITT Population.
Sexual Behavior and Adherence
The average number of male partners reported by participants in
the last 30 days decreased from 13 (SAVVY group) and 12.5
(placebo group) at the enrollment visit to 9 (SAVVY group) and
8.3 (placebo group) by the 12 month visit. Coital frequency
Randomized Trial of SAVVY Gel
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from 9.6 acts (SAVVY) and 9.5 (placebo) at the enrollment visit to
8.8 acts (SAVVY) and 8.3 acts (placebo) reported at the 12 month
visit.
Participants who became pregnant during the trial were asked
to stop gel use during pregnancy, but were told they could resume
product use after a negative pregnancy test. These participants
were included in the intent-to-treat analysis. A total of 272
participants in the SAVVY group and 280 participants in the
placebo group became pregnant at least once during the study.
The most common reason for product interruption was running
out of gel supplies, but pregnancy caused longer interruptions and
led to half of all observed person-time off product (not using gel),
about 5% of total person-time in both groups.
Participants reported that they used the gel for an average of
78% and 79% of coital acts in the SAVVY and placebo groups,
respectively, and reported condoms use for 87% of coital acts in
both the SAVVY and placebo groups (Table 2). They reported
using both gel and condoms for 69% and 70% of acts in the
SAVVY and placebo groups, respectively. Participants reported
using neither gel nor condoms for 5% and 4% of acts in the
SAVVY and placebo groups, respectively. Gel use reportedly
decreased slightly with time in both groups (from 85% at Month 1
to 80% at Month 12 in the SAVVY group, and from 86% at
Month-1 to 81% at Month 12 in the Placebo group). Condom use
also reportedly decreased over time in both groups (from 92% at
Month 1 to 87% at Month 12 in the SAVVY group, and from
91% at Month 1 to 87% at Month 12 for the Placebo group). We
calculated that SAVVY or placebo gel was used without condoms
for 8–9% of all vaginal sex acts and that condoms were used
without gel for 17–18% of all vaginal sex acts. Of the subset of
vaginal acts when a condom was not used, gel was reportedly used
for 62% of acts (Table 2).
Outcomes and Estimation
Thirteen infections occurred in Lagos, and 20 in Ibadan. The
overall HIV incidence rate was 1.87 per 100 person-years (95%
confidence interval [CI] 1.29, 2.63). Most seroconversions
occurred in younger participants: incidence rates were 2.17 per
100 person-years among women age 18–25 at screening; 1.13 per
100 among women age 26–30; and 0.85 per 100 among women
age 31–35.
We observed 33 seroconversions: 21 in the SAVVY group and
12 in the placebo group. The Kaplan-Meier estimates of the
cumulative probability of HIV infection at 12 months in the
Effectiveness Population were 0.028 in the SAVVY group and
Figure 1. Participant Trial Flow Diagram (P-Y, person years).
doi:10.1371/journal.pone.0001474.g001
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PLoS ONE | www.plosone.org 4 January 2008 | Issue 1 | e14740.015 in the placebo group. The two-sided p-value for the log-rank
test of treatment effect was 0.121. The point estimate of the hazard
ratio was 1.7 for SAVVY versus placebo (95% CI 0.9, 3.5;
Table 3).
Ancillary Analyses
Adjustment for study site and other pre-planned baseline variables
changed the SAVVY hazard ratio little (hazard ratio 1.8; 95% CI
0.9, 3.6; Table 3). None of the selected baseline covariates was
significantly associated with HIV infection. Examining pre-
planned subgroups of the Effectiveness Population, SAVVY was
significantly associated with HIV infection (p=0.009) in the
participants who reported an above median coital frequency
during follow-up (median 8–9 in the previous 7 days), and among
participants who reported an above median frequency of gel uses
(median 6–7 uses in the previous 7 days; p=0.002). There was
suggestive evidence (p=0.087) that SAVVY was associated with
HIV among women who reported above the median number of
partners (median 4 partners in previous 30 days). These factors
and frequency of condom use were highly correlated.
We repeated the analysis for the Evaluable Population, a subset
of the Effectiveness Population, excluding data collected from
participants after any documented interruption of product use.
Twelve HIV infections occurred in the Evaluable Population (7 in
the SAVVY group; 5 in the placebo group). The Kaplan-Meier
estimates of the cumulative probability of HIV infection at 12
months in the Evaluable Population were 0.020 in the SAVVY
group and 0.013 in the placebo group (2-sided p=0.449). The
unadjusted point estimate of the hazard ratio was 1.5 (95% CI 0.5,
4.8; Table 3).
Adverse Events
Adverse events (AEs) were reported by 624 of 1043 (60%)
participants in the SAVVY group and 636 of 1045 (61%)
participants in the placebo group. We found no significant
differences in frequency of AEs between treatment groups, either
overall or within any specific system organ class. The most
frequently reported non-reproductive tract AEs were malaria,
abdominal pain, and headache, reported by similar numbers of
SAVVY and placebo participants.
Reproductive tract AEs were reported by 327 of 1043 (31%)
SAVVY participants and 341 of 1045 (33%) placebo participants,
yielding an incidence rate ratio of 0.9 (95% CI 0.8, 1.1). The most
frequent self-reported reproductive AEs were vaginal candidiasis,
bacterial vaginosis, and vulvovaginitis. In post hoc analyses we
evaluated a subgroup of reproductive tract AEs that could be
reflective of genital irritation by the study gel, such as vaginal
irritation, vaginal burning, self-reported vaginitis, etc. (Table 4).
The incidence of these selected AEs was similar in both groups,
with an incidence rate ratio of 0.9 (95% CI 0.8, 1.1). We also
evaluated these reproductive AEs by categories of self-reported gel
use, to investigate a possible relationship between higher use of gel
and genital mucosal effects. The incidence of these reproductive
system and breast disorders was lower in the SAVVY group (36.8
per 100 person-years) than in the placebo group (42.5 per 100
person-years) among participants with self-reported gel use above
the median (data not shown).
Twenty-eight serious adverse events (SAEs) occurred during the
study. Thirteen SAEs were in the SAVVY group and 15 in the
placebo group; none was related to study product. Two
participants discontinued the study as a result of an SAE; one
was hospitalized for appendicitis and another was hospitalized for
typhoid enteritis. Information on the three participants who died
(one in the SAVVY group and two in the placebo group) was
limited. Two participants died at home of unknown causes. Both
were noted to be healthy at admission and had not made a study
visit for several months prior to death. Another participant had an
emergency cesarean delivery at 28 weeks’ gestation for pre-
eclampsia, and subsequently died of eclampsia.
Participants underwent pelvic examination for chlamydia
testing and saline wet mount examinations of vaginal secretions
at the 6-month follow-up visit and as needed. No significant
differences were seen; of the 1577 participants who had chlamydia
tests during follow-up, 4.1% were positive in the SAVVY group
and 3.8% in the placebo group. Among the 791 participants
who had wet mounts during follow-up, 27.3% of the SAVVY
group had bacterial vaginosis compared with 30.4% in the
placebo group; 38.0% of the SAVVY group had candidiasis
compared with 36.8% of placebo users; and 9.5% of the
SAVVY group had trichomoniasis compared with 11.5% of
placebo users.
Study Termination
The DMC met once prior to study initiation. During the trial, the
DMC reviewed interim HIV endpoint data (as well as supporting
data) for early evidence of SAVVY’s effectiveness or signs of
potential harm. One interim analysis was planned to look for early
evidence of harm when approximately one fourth (i.e., 16) of all
expected infections were observed. A second interim analysis was
Table 1. Baseline Characteristics (ITT Population).
......................................................................
Characteristic SAVVY (N=1076)
Placebo
(N=1077)
Age 23.5 (3.7) 23.6 (3.8)
Marital status
Unmarried, not living with a man 923 (85.9) 928 (86.2)
Education
.9 years 756 (70.3) 777 (72.1)
Occupation
Student 384 (35.7) 387 (35.9)
Trade/Commerce 384 (35.7) 392 (36.4)
Pregnancy history
Ever pregnant 800 (74.3) 804 (74.7)
Number of pregnancies 2.2 (1.4) 2.1 (1.4)
Number of vaginal deliveries 0.7 (1.0) 0.6 (1.0)
Contraceptive use
None 61 (5.7) 71 (6.6)
Condom only 776 (72.1) 742 (68.9)
Dual methods
(condom+contraceptive)
90 (8.4) 122 (11.3)
Oral 96 (8.9) 89 (8.3)
IUD 7 (0.7) 7 (0.6)
Injectable 6 (0.6) 10 (0.9)
Other 40 (3.7) 36 (3.3)
Self-reported history of STI 345 (32.1) 321 (29.8)
Previous spermicide use 25 (2.3) 25 (2.3)
Douching 661 (61.4) 653 (60.6)
Data reported as N (%) or mean (SD); SD=standard deviation, IUD=intrauterine
device; STI=sexually transmitted infection.
doi:10.1371/journal.pone.0001474.t001
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approximately one half (i.e., 33) of all expected infections were
observed. Given the low incidence rate, we did the mid-study
interim analysis at 29 events, at which time the study statistician
estimated that we would need to enroll approximately 1,980
additional participants to identify the 66 HIV infections that
would offer the desired study power. Due to concerns about the
feasibility of such expansion, we did a conditional power
calculation and asked the DMC to review the data and make a
recommendation on study continuation. The conditional power
analysis showed that the trial was unlikely to provide convincing
evidence of effectiveness even with the most optimistic projections.
The DMC recommended that the trial be stopped, and we
decided to terminate the study prematurely in August 2006.
DISCUSSION
We prematurely discontinued this study after the third DMC
meeting because the HIV incidence among enrolled participants
was less than one half the expected rate. Although the hazard ratio
was higher in the SAVVY than the placebo group (1.7; 95% CI
0.9 to 3.5), the two-sided p-value for the log-rank test of treatment
effect was 0.121 and we cannot conclude that SAVVY was
associated with higher levels of HIV infection. Because of our
stopping rule for futility and subsequent low power to detect a
Table 2. Estimates of Gel and Condom Use at Follow-Up by Treatment Groups*.
..................................................................................................................................................
Mean (median) percentage of reported vaginal sex acts in the last 7 days with
Treatment Visit
Mean (Median)
number of
reported vaginal
sex acts Study gel Condom
Study gel
and a
condom
Neither a
condom nor
study gel
Gel only
(without a
condom)
Condom only
(without study
gel)
Study gel when
a condom is not
used**
SAVVY (N=1076) Month 1 10.8 (9.0) 84.7 (100) 91.5 (100) 77.9 (95.1) 2.5 (0.0) 6.8 (0.0) 13.6 (0.0) 66.7 (100)
Month 6 9.8 (8.0) 75.7 (100) 86.5 (100) 67.2 (85.7) 4.8 (0.0) 8.5 (0.0) 19.3 (0.0) 62.5 (100)
Month 12 8.8 (7.0) 79.8 (100) 87.3 (100) 70.9 (100) 3.4 (0.0) 9.0 (0.0) 16.5 (0.0) 71.2 (100)
All FU Visits 10.2 (9.0) 77.9 (100) 87.0 (100) 69.4 (87.5) 4.7 (0.0) 8.5 (0.0) 17.8 (0.0) 62.0 (100)
Placebo (N=1077) Month 1 10.0 (8.0) 85.8 (100) 90.5 (100) 78.8 (100) 3.0 (0.0) 6.9 (0.0) 11.9 (0.0) 63.1 (100)
Month 6 10.0 (8.0) 80.7 (100) 87.0 (100) 71.2 (93.5) 3.7 (0.0) 9.6 (0.0) 15.8 (0.0) 65.3 (100)
Month 12 8.3 (6.0) 80.5 (100) 86.6 (100) 72.3 (100) 4.0 (0.0) 8.2 (0.0) 14.4 (0.0) 68.9 (100)
All FU Visits 9.8 (8.0) 79.1 (100) 86.7 (100) 70.3 (90.0) 4.4 (0.0) 8.8 (0.0) 16.6 (0.0) 61.7 (100)
*For each participant and variable of interest (e.g., percentage of vaginal acts where study gel was used in the last 7 days prior to the follow-up visit), we first calculated
the participant’s mean value of the variable of interest across all of their follow-up visits. (Follow-up visits where women reported a missing number of vaginal sex acts
in the last 7 days are excluded from the calculation of a participant’s mean value.) The median values of the distributions of these mean values were then obtained for
each treatment group.
**Study gel when a condom is not used refers to the percentage of condom-free sex acts where gel was used.
doi:10.1371/journal.pone.0001474.t002
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Table 3. Hazard Ratio of Incident HIV Infection (SAVVY versus Placebo) with and without Adjustment for Baseline Covariates in
Effectiveness and Evaluable Populations.
..................................................................................................................................................
Study Population Model Effect Hazard Ratio (95% CI) P-value (2-sided)
Effectiveness M1
a SAVVY (vs Placebo) 1.7 (0.9, 3.5) 0.127
M2
b SAVVY (vs Placebo) 1.7 (0.9, 3.5) 0.126
Ibadan (vs Lagos) 1.1 (0.6, 2.3) 0.708
M3
c SAVVY (vs Placebo) 1.8 (0.9, 3.6) 0.113
Ibadan (vs Lagos) 0.9 (0.4, 1.9) 0.859
Ever been pregnant 1.4 (0.6, 3.3) 0.400
Previous experience using spermicides 2.8 (0.7, 11.9) 0.157
No. of male partners 0.9 (0.9, 1.0) 0.187
No. of sex acts not protected by condoms 1.0 (0.7, 1.3) 0.807
Positive GC or CT at baseline 1.8 (0.4, 7.8) 0.412
Evaluable
* M1
a SAVVY (vs Placebo) 1.5 (0.5, 4.8) 0.471
M2
b SAVVY (vs Placebo) 1.5 (0.5, 4.9) 0.459
Ibadan (vs Lagos) 0.1 (0.0, 1.2) 0.070
aModel M1: treatment effect without adjustment for covariates.
bModel M2: treatment effect adjusted for site.
cModel M3: treatment effect adjusted for site and other baseline covariates, including ever been pregnant, previous experience using spermicides, number of different
male partners, number of vaginal sex acts not protected by condoms, and positive GC or CT at baseline.
*Model that adjusted for site and baseline covariates was not implemented for Evaluable population due to small number of events.
doi:10.1371/journal.pone.0001474.t003
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PLoS ONE | www.plosone.org 6 January 2008 | Issue 1 | e1474harmful effect, the absence of a statistically significant finding
cannot be taken as evidence of no association. Thus we cannot
rule out the possibility that SAVVY increases the risk of HIV
among certain users, such as women with above median coital
frequency, numbers of partners, or gel use. But those pre-planned
subgroup analyses are not conclusive and should be interpreted
with caution. [18] The small number of events and the absence of
supporting evidence in the similar FHI SAVVY trial in Ghana
[19] make this a challenging question that we are unlikely to
answer conclusively.
We did not observe significant differences in adverse events
among participants receiving SAVVY compared with those
receiving placebo, including within the category of reproductive
tract/breast disorders. Most of the AEs deemed related to product
use were in the reproductive system, and more of them were in the
SAVVY group than the placebo group, but they were almost
invariablyslightormild.Also,wefoundnoevidenceofincreasedrisk
of chlamydial or vaginal infections in SAVVY users. Three deaths
were reported, but none appeared related to gel use. Our data
indicate that use of SAVVY gel does not lead to notable side effects.
During follow-up, participants reported an average of 10 coital
acts per week, with an average of 9 sexual partners in the previous
30 days. Reported condom use during follow-up increased from
67% during the last coital act prior to screening to over 90% at the
first follow-up visit, remaining over 80% in both groups
throughout the follow-up period. Thus, the availability of study
gel products did not result in measurably increased risk-taking
behaviors among our study participants.
Interpretation
A number of factors can conspire to render microbicide trials
uninformative. Lower than expected HIV incidence, such as we
observed in this trial, has been measured in other microbicide
trials as well as oral pre-exposure prophylaxis (PrEP) HIV
prevention trials. [20] Diminished HIV incidence within a clinical
trial may follow from vigorous responses to trial risk-reduction
measures, as well as the phenomenon that participants who join
clinical trials differ from others in the wider community, [21] in
this case a possible inclination to safer behavior. We did not
directly measure HIV incidence at the study sites before the trial;
Table 4. Selected Priority Adverse Events.
..................................................................................................................................................
SAVVY (N=1043) Placebo (N=1045)
System Organ Class/Preferred Term
Number of
Events
Number of
Women
Percent of
Women IR
*
Number of
Events
Number of
Women
Percent of
Women IR
**
Rate Ratio (95% CI)
SAVVY vs. Placebo
Reproductive system and breast
disorders
**
459 293 28.1 38.8 444 317 30.3 42.8 0.9 (0.8, 1.1)
....Vaginal candidiasis 168 151 14.5 18.0 152 141 13.5 16.8 1.1 (0.8, 1.4)
....Vaginosis bacterial 112 109 10.5 12.9 117 114 10.9 13.5 1.0 (0.7, 1.3)
....Vulvovaginal pruritus 71 62 5.9 7.1 55 53 5.1 6.1 1.2 (0.8, 1.7)
....Vulvovaginitis trichomonal 39 38 3.6 4.3 47 45 4.3 5.1 0.8 (0.5, 1.3)
....Vaginal discharge 28 27 2.6 3.1 21 20 1.9 2.3 1.3 (0.7, 2.5)
....Genital abscess 7 7 0.7 0.8 11 11 1.1 1.2 0.6 (0.2, 1.8)
....Menstruation irregular 4 4 0.4 0.3 7 7 0.7 0.8 0.4 (0.1, 1.9)
....Vaginal erythema 6 6 0.6 0.7 3 3 0.3 0.3 2.0 (0.4, 12.4)
....Vaginal burning sensation 5 5 0.5 0.6 3 3 0.3 0.3 1.7 (0.3, 10.7)
....Vulvovaginitis 2 2 0.2 0.2 5 5 0.5 0.6 0.4 (0.0, 2.4)
....Genital pain 4 4 0.4 0.4 2 2 0.2 0.2 2.0 (0.3, 22.1)
....Genital rash 4 4 0.4 0.4 2 2 0.2 0.2 2.0 (0.3, 22.1)
....Menorrhagia 3 3 0.3 0.3 3 3 0.3 0.3 1.0 (0.1, 7.4)
....Dyspareunia 3 3 0.3 0.3 2 2 0.2 0.2 1.5 (0.2, 17.9)
....Vaginal haemorrhage 1 1 0.1 0.1 4 4 0.4 0.4 0.2 (0.0, 2.5)
....Menstrual disorder 0 0 0.0 0.0 3 3 0.3 0.3 0.0 (0.0, 2.4)
....Genital lesion 0 0 0.0 0.0 2 2 0.2 0.2 0.0 (0.0, 5.3)
....Vaginal laceration 1 1 0.1 0.1 1 1 0.1 0.1 1.0 (0.0, 78.3)
....Vaginitis 0 0 0.0 0.0 2 2 0.2 0.2 0.0 (0.0, 5.3)
....Oedema genital 1 1 0.1 0.1 0 0 0.0 0.0 -
....Vaginal lesion 0 0 0.0 0.0 1 1 0.1 0.1 0.0 (0.0, 38.9)
....Vaginal ulceration 0 0 0.0 0.0 1 1 0.1 0.1 0.0 (0.0, 38.9)
Gastrointestinal disorders 126 109 10.5 13.0 130 111 10.6 13.2 1.0 (0.7, 1.3)
Pregnancy, puerperium and perinatal
conditions
0 0 0.0 0.0 3 3 0.3 0.3 0.0 (0.0, 2.4)
Renal and urinary disorders 18 16 1.5 1.8 14 11 1.1 1.2 1.5 (0.6, 3.5)
*Incidence rate per 100 person-years of follow-up. Excludes events with missing onset dates.
**Selected reproductive system adverse events that could be related to genital irritation. The incidence rate ratio for all adverse events in the reproductive and breast
system organ class was 0.9 (0.8, 1.1).
doi:10.1371/journal.pone.0001474.t004
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PLoS ONE | www.plosone.org 7 January 2008 | Issue 1 | e1474even a prospective cohort study would be no guarantee of future
incidence since local HIV epidemics are so dynamic.
Second, achieving high adherence with product use is a
challenge in HIV prevention studies. More than any other single
factor (including low HIV incidence), low adherence compromises
the power of a prevention trial. [22] We suspect over-reporting of
adherence in this trial: despite SAVVY’s purported contraceptive
effect, [11] the similar pregnancy rates in the two groups raises
doubt that the gels were used as consistently as reported.
A third challenge to measuring microbicide effectiveness is
condom use. Although gel was reportedly used during approxi-
mately 78% of coital acts in this trial, condom use was even more
common and participants were more likely to use gel if a condom
was also used. Gel was reportedly used alone (i.e., without a
condom) for only about 9% of all coital acts. If true, this too would
render it difficult to detect a difference in HIV incidence, since
that difference could only arise from a relatively small proportion
of potential exposures.
Finally, the occurrence of anal intercourse complicates analysis
of topical vaginal agents. Participants were instructed to use the
study product only in their vagina. However, at screening 8% of
women reported ever having anal sex, and at enrollment
approximately 4% of the participants reported having had anal
sex and within the last 30 days. HIV transmission studies have
indicated that the risk of HIV infection is greater from receptive
anal intercourse than receptive vaginal intercourse. [23–25]
Therefore, some of the seroconversions seen in this vaginal
microbicide study could be due to HIV exposure through anal
intercourse, with an equal probability of infection regardless of
treatment group and resulting bias towards no apparent effect on
vaginal transmission.
Generalizability
These challenges may contribute to the discrepant results reported
for recent placebo-controlled microbicide trials. One N-9 trial
reported no difference in HIV incidence, [26] while the second
reported a higher incidence in the treatment group. [7] The same
pattern prevailed in the pair of SAVVY trials, [19] and two as-yet
unpublished trials of cellulose sulfate. [Halpern V, Wang L,
Obunge O, Ogunsola F, Mehta N, et al. (2007) Effectiveness of
cellulose sulfate gel for prevention of HIV: results of the phase III
trial in Nigeria. 4th International AIDS Society Conference on
HIV Pathogenesis, Treatment, and Prevention. Sydney, Australia,
July 22–25, 2007. Abstract WESS302; and Van Damme L,
Govinden R, Mirembe F, Guedou F, Solomon S, et al. (2007)
Phase III trial of 6% cellulose sulfate (CS) gel for the prevention of
HIV transmission. 4th International AIDS Society Conference on
HIV Pathogenesis, Treatment, and Prevention. Sydney, Australia,
July 22–25, 2007. Abstract WESS301] The wisdom of the U.S.
Food and Drug Administration requirement for two trial results
significant at the 0.05 level is apparent. [27]
Overall Evidence
As a new HIV prevention approach, microbicides could be used
with other prevention strategies such as condoms to reduce the
number of people who become infected with HIV. More powerful
Phase 3 studies in higher incidence cohorts are needed to
determine conclusively the effectiveness, safety and feasibility of
using microbicides for prevention of HIV infection in women.
This trial provides no evidence for benefits from SAVVY use.
SUPPORTING INFORMATION
Checklist S1 CONSORT Checklist
Found at: doi:10.1371/journal.pone.0001474.s001 (0.06 MB
DOC)
Protocol S1 Amended study protocol as implemented in the
field
Found at: doi:10.1371/journal.pone.0001474.s002 (0.83 MB
DOC)
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